Global Swine Vaccines Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

Description

List of Tables

Global Swine Vaccines Market size is anticipated to grow from USD 2.16 Billion in 2024 to USD 3.49 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 5.49% during the forecast period of 2026 to 2033.

The swine vaccines market is set for robust growth, driven by the increasing prevalence of infectious diseases affecting pig populations. As the global demand for pork continues to rise, the need for effective vaccination strategies to ensure herd health and productivity becomes paramount. The emergence of novel pathogens and the resurgence of previously controlled diseases necessitate ongoing research and development in vaccine formulations. Companies are investing heavily in innovative technologies, such as recombinant vaccines and mRNA-based solutions, which promise enhanced efficacy and safety profiles, thereby addressing the evolving challenges faced by swine producers.

Moreover, the growing awareness of biosecurity measures among livestock farmers is significantly influencing the swine vaccines market. Producers are increasingly recognizing the importance of vaccination as a critical component of comprehensive herd management strategies. This shift in mindset is fostering a proactive approach to disease prevention, leading to higher vaccination rates and, consequently, a more resilient swine population. The integration of digital tools for monitoring and managing vaccination schedules is also gaining traction, enabling farmers to optimize their herd health management practices and improve overall productivity.

Additionally, the expansion of the global swine industry, particularly in emerging markets, presents lucrative opportunities for the swine vaccines market. As countries strive to enhance their livestock production capabilities to meet growing consumer demand, the adoption of advanced vaccination programs becomes essential. Collaborations between vaccine manufacturers and agricultural organizations are expected to facilitate knowledge transfer and improve access to vaccination technologies in these regions. The future of the swine vaccines market appears promising, characterized by continuous innovation, increased awareness of disease management, and a commitment to enhancing animal health and welfare.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Product

Inactivated vaccines
Live attenuated vaccines
Recombinant vaccines
Subunit vaccines
Toxoid vaccines
Other products

By Disease Type

Porcine reproductive and respiratory syndrome (PRRS)
Porcine circovirus type 2 (PCV2)
Mycoplasma hyopneumoniae
Classical swine fever (CSF)
Swine influenza
Erysipelas
Foot-and-Mouth disease (FMD)
African swine fever (ASF)
Porcine parvovirus
Other disease types

By End-user

Veterinary hospitals & clinics
Swine farms
Research institutes
COMPANIES PROFILED
Biogenesis Bago
Bioveta
Boehringer Ingelheim International GmbH
Ceva Sante Animale
Elanco Animal Health Incorporated
HIPRA
Indian Immunologicals Limited
Merck & Co. Inc.
Phibro Animal Health Corporation
Vaxxinova
Virbac
Zoetis Inc.
The above list can be customized.

Product Code: VMR11214069

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. SWINE VACCINES INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Disease Type
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL SWINE VACCINES MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data Analysis By Product
5.3. Inactivated vaccines Historic and Forecast Sales By Regions
5.4. Live attenuated vaccines Historic and Forecast Sales By Regions
5.5. Recombinant vaccines Historic and Forecast Sales By Regions
5.6. Subunit vaccines Historic and Forecast Sales By Regions
5.7. Toxoid vaccines Historic and Forecast Sales By Regions
5.8. Other products Historic and Forecast Sales By Regions

6. GLOBAL SWINE VACCINES MARKET ANALYSIS BY DISEASE TYPE

6.1. Overview By Disease Type
6.2. Historical and Forecast Data Analysis By Disease Type
6.3. Porcine reproductive and respiratory syndrome (PRRS) Historic and Forecast Sales By Regions
6.4. Porcine circovirus type 2 (PCV2) Historic and Forecast Sales By Regions
6.5. Mycoplasma hyopneumoniae Historic and Forecast Sales By Regions
6.6. Classical swine fever (CSF) Historic and Forecast Sales By Regions
6.7. Swine influenza Historic and Forecast Sales By Regions
6.8. Erysipelas Historic and Forecast Sales By Regions
6.9. Foot-and-Mouth disease (FMD) Historic and Forecast Sales By Regions
6.10. African swine fever (ASF) Historic and Forecast Sales By Regions
6.11. Porcine parvovirus Historic and Forecast Sales By Regions
6.12. Other disease types Historic and Forecast Sales By Regions

7. GLOBAL SWINE VACCINES MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data Analysis By End-user
7.3. Veterinary hospitals & clinics Historic and Forecast Sales By Regions
7.4. Swine farms Historic and Forecast Sales By Regions
7.5. Research institutes Historic and Forecast Sales By Regions

8. GLOBAL SWINE VACCINES MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE SWINE VACCINES COMPANIES

9.1. Swine Vaccines Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF SWINE VACCINES INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Biogenesis Bago
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Bioveta
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Boehringer Ingelheim International GmbH
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Ceva SantA(C) Animale
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Elanco Animal Health Incorporated
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. HIPRA
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Indian Immunologicals Limited
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Merck & Co. Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Phibro Animal Health Corporation
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Vaxxinova
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Virbac
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Zoetis Inc
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies